
Protalix BioTherapeutics, Inc.
AMEX:PLX
Overview | Financials
Company Name | Protalix BioTherapeutics, Inc. |
Symbol | PLX |
Currency | USD |
Price | 1.4 |
Market Cap | 100,213,120 |
Dividend Yield | 0% |
52-week-range | 1.03 - 3.55 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Dror Bashan |
Website | https://www.protalix.com |
An error occurred while fetching data.
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD